It is well-known that pembrolizumab enhances the effector function of T cells by blocking the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, but the implications of this blockade on the composition and properties of tumor microenvironment are not clear. This evidence concerns the gene CD274 and neoplasm.